Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022
November 08, 2022 at 04:11 pm EST
Share
Anika Therapeutics, Inc. provided revenue guidance for the fiscal year 2022. For the period, the company continues to expect its overall revenue to be toward the upper end of its guidance range of low to mid single-digit growth compared with 2021. Revenue ranges by product family are: OA Pain Management up mid to upper single-digit percent (previously low single-digit percent), Joint Preservation and Restoration up low to mid single-digit percent (previously mid single to low double-digit percent) and Non-Orthopedic down approximately 20% due largely to legacy product rationalization.
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
ANIKA THERAPEUTICS, INC. 
